2.4900 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||2.4800 x 28000|
|Ask||2.4900 x 900|
|Day's Range||2.4200 - 2.5000|
|52 Week Range||1.9600 - 3.6500|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the...
Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters ...
SOUTH SAN FRANCISCO, Calif. , May 31, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present ...
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolytic anemia (AIHA). "Enrolling the first patient in our Phase 3 clinical trial of fostamatinib in warm AIHA is an important milestone in our efforts to develop the first FDA-approved therapy for this disease," stated Raul Rodriguez, president and CEO.
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...
TAVALISSE® net product sales of $8.1 million on 1,019 bottles, a 10% increase quarter-over-quarter Total revenues of $12.6 million , including $4.6 million from collaborations Opened clinical trial sites ...
SOUTH SAN FRANCISCO, Calif. , April 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2019 financial results after market close on ...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. After all...
SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ --Rigel Pharmaceuticals, Inc. (RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of experience in the biopharma industry working with both large, multinational corporations and privately held start-ups. The wealth of strategic, operational and legal knowledge she brings to the company will be invaluable as we continue to expand our potential market opportunity," said Raul Rodriguez, president and CEO of Rigel.
Raul Rodriguez has been the CEO of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
Fourth quarter total revenues of $37.9 million ; full year total revenues of $44.5 million Fourth quarter net product sales of $7.3 million ; full year net product sales of $13.9 million Conference call ...
SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2018 financial results after market ...